{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:04:15Z","timestamp":1793747055144,"version":"4.6.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100021049","name":"Imunon","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ygyno.2025.04.578","type":"journal-article","created":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T20:02:11Z","timestamp":1748894531000},"page":"182-191","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["OVATION-2: A randomized phase I\/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo\/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer"],"prefix":"10.1016","volume":"197","author":[{"given":"Premal H.","family":"Thaker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra L.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea R.","family":"Hagemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"Holloway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie K.","family":"Bergman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavana","family":"Pothuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"DePasquale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer M.","family":"Scalici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy J.","family":"Bregar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Darus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Finkelstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Charles A.","family":"Leath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Warshal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richy","family":"Agajanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan D.","family":"Indermaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto A.","family":"Mendivil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane M.","family":"Provencher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee-Jen","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Borys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Musso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacy R.","family":"Lindborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas V.","family":"Faller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khursheed","family":"Anwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Bradley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ygyno.2025.04.578_bb0005","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"issue":"Suppl. 6","key":"10.1016\/j.ygyno.2025.04.578_bb0010","doi-asserted-by":"crossref","first-page":"vi24","DOI":"10.1093\/annonc\/mdt333","article-title":"Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Ledermann","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2025.04.578_bb0015","article-title":"Epithelial ovarian cancer: review article","volume":"33","author":"Sambasivan","year":"2022","journal-title":"Cancer Treat Res. Commun."},{"issue":"2","key":"10.1016\/j.ygyno.2025.04.578_bb0020","article-title":"Surgical cytoreduction for recurrent epithelial ovarian cancer","volume":"2013","author":"Al Rawahi","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"issue":"18","key":"10.1016\/j.ygyno.2025.04.578_bb0025","doi-asserted-by":"crossref","DOI":"10.1172\/JCI184846","article-title":"Checkpoint therapy in cancer treatment: progress, challenges, and future directions","volume":"134","author":"Bicak","year":"2024","journal-title":"J. Clin. Invest."},{"issue":"26","key":"10.1016\/j.ygyno.2025.04.578_bb0030","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.ygyno.2025.04.578_bb0035","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1056\/NEJMoa1909707","article-title":"Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2025.04.578_bb0040","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40661-016-0033-6","article-title":"The role of immune checkpoint inhibition in the treatment of ovarian cancer","volume":"3","author":"Gaillard","year":"2016","journal-title":"Gynecol. Oncol. Res. Pract."},{"issue":"11","key":"10.1016\/j.ygyno.2025.04.578_bb0045","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.annonc.2024.08.2241","article-title":"Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA\/ENGOT-OV26\/GOG-3012 trial","volume":"35","author":"Monk","year":"2024","journal-title":"Ann. Oncol."},{"issue":"26","key":"10.1016\/j.ygyno.2025.04.578_bb0050","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance Olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.ygyno.2025.04.578_bb0055","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/s41568-022-00503-z","article-title":"Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation","volume":"22","author":"Kandalaft","year":"2022","journal-title":"Nat. Rev. Cancer"},{"issue":"suppl_8","key":"10.1016\/j.ygyno.2025.04.578_bb0060","doi-asserted-by":"crossref","first-page":"viii1","DOI":"10.1093\/annonc\/mdx444","article-title":"Immunotherapy in ovarian cancer","volume":"28","author":"Odunsi","year":"2017","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2025.04.578_bb0065","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00005-022-00655-8","article-title":"Immunotherapy in ovarian cancer","volume":"70","author":"Siminiak","year":"2022","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"10.1016\/j.ygyno.2025.04.578_bb0070","doi-asserted-by":"crossref","first-page":"1328651","DOI":"10.3389\/fimmu.2023.1328651","article-title":"Targeting the immune microenvironment for ovarian cancer therapy","volume":"14","author":"Blanc-Durand","year":"2023","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.ygyno.2025.04.578_bb0075","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1080\/08830185.2016.1206097","article-title":"Tumor-associated macrophages and myeloid-derived suppressor cells as immunosuppressive mechanism in ovarian cancer patients: progress and challenges","volume":"35","author":"Okla","year":"2016","journal-title":"Int. Rev. Immunol."},{"issue":"12","key":"10.1016\/j.ygyno.2025.04.578_bb0080","doi-asserted-by":"crossref","first-page":"13587","DOI":"10.18632\/oncotarget.7277","article-title":"Association and prognostic significance of BRCA1\/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1\/PD-L1 in high grade serous ovarian cancer","volume":"7","author":"Strickland","year":"2016","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.ygyno.2025.04.578_bb0085","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1080\/08820139.2016.1186689","article-title":"Minireview: regulatory T cells and ovarian cancer","volume":"45","author":"Singh","year":"2016","journal-title":"Immunol. Investig."},{"issue":"3","key":"10.1016\/j.ygyno.2025.04.578_bb0090","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa020177","article-title":"Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer","volume":"348","author":"Zhang","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"51","key":"10.1016\/j.ygyno.2025.04.578_bb0095","doi-asserted-by":"crossref","first-page":"18538","DOI":"10.1073\/pnas.0509182102","article-title":"Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+\/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer","volume":"102","author":"Sato","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ygyno.2025.04.578_bb0100","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu. Rev. Pathol."},{"issue":"7","key":"10.1016\/j.ygyno.2025.04.578_bb0105","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","article-title":"Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study","volume":"30","author":"Matulonis","year":"2019","journal-title":"Ann. Oncol."},{"issue":"7","key":"10.1016\/j.ygyno.2025.04.578_bb0110","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S1470-2045(21)00216-3","article-title":"Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN ovarian 200): an open-label, three-arm, randomised, phase 3 study","volume":"22","author":"Pujade-Lauraine","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2025.04.578_bb0115","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ygyno.2024.10.022","article-title":"Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR\/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO\/GOG-3031\/RUBY)","volume":"192","author":"Powell","year":"2025","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2025.04.578_bb0120","series-title":"News Release","article-title":"GSK announces FIRST trial met its primary endpoint of progression free survival in first line advanced ovarian cancer","author":"GSK","year":"2024"},{"key":"10.1016\/j.ygyno.2025.04.578_bb0125","author":"Harter","year":"2024"},{"issue":"3","key":"10.1016\/j.ygyno.2025.04.578_bb0130","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ygyno.2014.03.571","article-title":"A phase II trial of intraperitoneal EGEN-001, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: a gynecologic oncology group study","volume":"133","author":"Alvarez","year":"2014","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2025.04.578_bb0135","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/gt.2009.159","article-title":"Phase-I clinical trial of IL-12 plasmid\/lipopolymer complexes for the treatment of recurrent ovarian cancer","volume":"17","author":"Anwer","year":"2010","journal-title":"Gene Ther."},{"issue":"20","key":"10.1016\/j.ygyno.2025.04.578_bb0140","doi-asserted-by":"crossref","first-page":"5536","DOI":"10.1158\/1078-0432.CCR-21-0360","article-title":"GEN-1 in combination with neoadjuvant chemotherapy for patients with advanced epithelial ovarian Cancer: a phase I dose-escalation study","volume":"27","author":"Thaker","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.ygyno.2025.04.578_bb0145","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1006\/gyno.2001.6255","article-title":"Evaluation of recombinant human interleukin-12 in patients with recurrent or refractory ovarian cancer: a gynecologic oncology group study","volume":"82","author":"Hurteau","year":"2001","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2025.04.578_bb0150","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.952231","article-title":"IL12 immune therapy clinical trial review: novel strategies for avoiding CRS-associated cytokines","volume":"13","author":"Jia","year":"2022","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.ygyno.2025.04.578_bb0155","first-page":"2541","article-title":"Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production","volume":"90","author":"Leonard","year":"1997","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ygyno.2025.04.578_bb0160","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.19055","article-title":"Using a clinically interpretable end point composed of multiple outcomes to evaluate totality of treatment effect in comparative oncology studies","volume":"6","author":"Wang","year":"2023","journal-title":"JAMA Netw. Open"},{"issue":"11","key":"10.1016\/j.ygyno.2025.04.578_bb0165","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1158\/2159-8290.CD-15-0714","article-title":"Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer","volume":"5","author":"Konstantinopoulos","year":"2015","journal-title":"Cancer Discov."},{"issue":"21","key":"10.1016\/j.ygyno.2025.04.578_bb0170","doi-asserted-by":"crossref","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","article-title":"Hallmarks of response, resistance, and toxicity to immune checkpoint blockade","volume":"184","author":"Morad","year":"2021","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.ygyno.2025.04.578_bb0175","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41467-023-44310-y","article-title":"IL-12 reprograms CAR-expressing natural killer T cells to long-lived Th1-polarized cells with potent antitumor activity","volume":"15","author":"Landoni","year":"2024","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.ygyno.2025.04.578_bb0180","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13020167","article-title":"IL-12 family cytokines in cancer and immunotherapy","volume":"13","author":"Mirlekar","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.ygyno.2025.04.578_bb0185","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1002\/(SICI)1521-4141(199906)29:06<1762::AID-IMMU1762>3.0.CO;2-F","article-title":"IL-12 directly up-regulates the expression of HLA class I, HLA class II and ICAM-1 on human melanoma cells: a mechanism for its antitumor activity?","volume":"29","author":"Yue","year":"1999","journal-title":"Eur. J. Immunol."},{"issue":"6","key":"10.1016\/j.ygyno.2025.04.578_bb0190","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1158\/2159-8290.CD-18-1218","article-title":"PARP inhibitor efficacy depends on CD8(+) T-cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer","volume":"9","author":"Pantelidou","year":"2019","journal-title":"Cancer Discov."},{"issue":"11","key":"10.1016\/j.ygyno.2025.04.578_bb0195","doi-asserted-by":"crossref","first-page":"7618","DOI":"10.4049\/jimmunol.177.11.7618","article-title":"IL-12-programmed long-term CD8+ T cell responses require STAT4","volume":"177","author":"Li","year":"2006","journal-title":"J. Immunol."}],"updated-by":[{"DOI":"10.1016\/j.ygyno.2025.10.031","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000}}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825825007978?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825825007978?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T13:07:09Z","timestamp":1791983229000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825825007978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":39,"alternative-id":["S0090825825007978"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.04.578","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"OVATION-2: A randomized phase I\/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo\/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.04.578","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}